Among them, TRAIL appears to be the most promising candidate therapeutic for targeted therapy for cancer in clinic since it preferentially initiates apoptosis in a broad variety of tumor cells without overt cytotoxicity to normal cells both in vitro and in vivo [4,5]. Here, TNFSF10 is linked to neoplasm.